Developing Psychedelic Therapies for Addiction

We are developing evidence-based, patent-protected, synthetically-derived psychedelic therapeutics to transform the treatment of addiction, starting with synthetic Mescaline HCl (JOUR-5700) for the treatment of alcohol use disorder.